Gilead Sciences, Inc.
Close on Nov 2, 2026Market cap $211.20BP/E –Yield 1.86%
Gilead Sciences Arcus revenue from Gilead by Quarter
Arcus revenue from Gilead — License & development services (legacy axis, $M) ($M)
Gilead Sciences Arcus revenue from Gilead: $8M in Q2 2026, down 94.7% from a year earlier.
Where the Q2 2026 figure comes from
Source: Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗
Reported in Arcus Biosciences (RCUS) Form 10-Q / 10-K.
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus revenue from Gilead — License & development services (legacy axis, $M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 8 | -94.7% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 10 | -50.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗ |
| Q2 2025 | Jun 30, 2025 | 152 | – | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2025 | Mar 31, 2025 | 20 | – | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus revenue from Gilead ($M), quarterly Q1 2025–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus-rev-gilead-lic
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.